Evidence map›Paper›PMID 32452208›Full record

Trial reportThe American journal of sports medicine2020

The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial.

Christopher L Mendias, Elizabeth R Sibilsky Enselman, Adam M Olszewski, Jonathan P Gumucio, Daniel L Edon, Maxwell A Konnaris, James E Carpenter, Tariq M Awan, Jon A Jacobson, Joel J Gagnier and 2 more

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of sports medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02420353 phase2completednot on this map

Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears

TypeinterventionalSponsorUniversity of MichiganRan2015 to 2018Enrolled20ConditionsRupture of Anterior Cruciate LigamentArmsSomatropin, Placebo
NCT07036003 phase1 / phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation

Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR): a Pilot, Randomized Placebo-controlled Trial

TypeinterventionalSponsorDr. David WassersteinRan2025 to 2029Enrolled34ConditionsKnee Osteoarthritis (Knee OA), Knee Osteoarthritis (OA)ArmsSomatropin (recombinant human growth hormone), bacteriostatic saline placebo
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Christopher L MendiasHospital for Special Surgery, New York, New York, USA.
Elizabeth R Sibilsky EnselmanDepartment of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Adam M OlszewskiDepartment of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jonathan P GumucioDepartment of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Daniel L EdonHospital for Special Surgery, New York, New York, USA.
Maxwell A KonnarisHospital for Special Surgery, New York, New York, USA.
James E CarpenterDepartment of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Tariq M AwanDepartment of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Jon A JacobsonDepartment of Radiology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Joel J GagnierDepartment of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Ariel L BarkanDivision of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Asheesh BediDepartment of Orthopaedic Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
University of Michigan–Ann Arbor · USHospital for Special Surgery · US

Funding

Fatty Macrophage Regulation of Atrophy and Inflammation in Rotator Cuff TearsF31AR065931 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUMUCIO, JONATHAN PAUL · 2014 to 2016
$103k
NIAMS NIH HHS F31 AR065931
6 · The paper itself

Abstract

backgroundAnterior cruciate ligament (ACL) tears are common knee injuries. Despite undergoing extensive rehabilitation after ACL reconstruction (ACLR), many patients have persistent quadriceps muscle weakness that limits their successful return to play and are also at an increased risk of developing knee osteoarthritis (OA). Human growth hormone (HGH) has been shown to prevent muscle atrophy and weakness in various models of disuse and disease but has not been evaluated in patients undergoing ACLR. HYPOTHESIS: Compared with placebo treatment, a 6-week perioperative treatment course of HGH would protect against muscle atrophy and weakness in patients undergoing ACLR. STUDY

designRandomized controlled trial; Level of evidence, 2.

methodsA total of 19 male patients (aged 18-35 years) scheduled to undergo ACLR were randomly assigned to the placebo (n = 9) or HGH (n = 10) group. Patients began placebo or HGH treatment twice daily 1 week before surgery and continued through 5 weeks after surgery. Knee muscle strength and volume, patient-reported outcome scores, and circulating biomarkers were measured at several time points through 6 months after surgery. Mixed-effects models were used to evaluate differences between treatment groups and time points, and as this was a pilot study, significance was set at

resultsHGH was well-tolerated, and no differences in adverse events between the groups were observed. The HGH group had a 2.1-fold increase in circulating insulin-like growth factor 1 over the course of the treatment period (

conclusionHGH improved quadriceps strength and reduced MMP3 levels in patients undergoing ACLR. On the basis of this pilot study, further trials to more comprehensively evaluate the ability of HGH to improve muscle function and potentially protect against OA in patients undergoing ACLR are warranted. REGISTRATION: NCT02420353 ( ClinicalTrials.gov identifier).

Indexed as

Anterior Cruciate Ligament InjuriesAnterior Cruciate Ligament ReconstructionAdolescentAdultHuman Growth HormoneHumansKnee JointMaleMuscle StrengthMuscle WeaknessPilot ProjectsQuadriceps MuscleRecombinant ProteinsYoung AdultHuman Growth HormoneRecombinant Proteinsanterior cruciate ligamenthuman growth hormonemuscle atrophyorthobiologicssomatropin

Identifiers

PMID32452208
PMCPMC7351248
OpenAlexW3032444789

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.